210 related articles for article (PubMed ID: 34427452)
1. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in
Doebele RC; Perez L; Trinh H; Martinec M; Martina R; Riehl T; Krebs MG; Meropol NJ; Wong WB; Crane G
J Comp Eff Res; 2021 Dec; 10(17):1271-1282. PubMed ID: 34427452
[No Abstract] [Full Text] [Related]
2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of crizotinib versus entrectinib in
Tremblay G; Groff M; Iadeluca L; Daniele P; Wilner K; Wiltshire R; Bartolome L; Usari T; Cappelleri JC; Camidge DR
Future Oncol; 2022 Jun; 18(17):2063-2074. PubMed ID: 35232230
[No Abstract] [Full Text] [Related]
4. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
[TBL] [Abstract][Full Text] [Related]
5. Matching-adjusted indirect comparison: entrectinib versus crizotinib in
Chu P; Antoniou M; Bhutani MK; Aziez A; Daigl M
J Comp Eff Res; 2020 Aug; 9(12):861-876. PubMed ID: 32648475
[No Abstract] [Full Text] [Related]
6. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Entrectinib in
Drilon A; Chiu CH; Fan Y; Cho BC; Lu S; Ahn MJ; Krebs MG; Liu SV; John T; Otterson GA; Tan DSW; Patil T; Dziadziuszko R; Massarelli E; Seto T; Doebele RC; Pitcher B; Kurtsikidze N; Heinzmann S; Siena S
JTO Clin Res Rep; 2022 Jun; 3(6):100332. PubMed ID: 35663414
[TBL] [Abstract][Full Text] [Related]
8. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
9. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of crizotinib in patients with
Nogami N; Nakamura A; Shiraiwa N; Kikkawa H; Emir B; Wiltshire R; Morise M
Future Oncol; 2023 Dec; 19(37):2453-2463. PubMed ID: 37605861
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
[TBL] [Abstract][Full Text] [Related]
12. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
13. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
14. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract][Full Text] [Related]
15. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
[TBL] [Abstract][Full Text] [Related]
17. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
Osman HM; Tuncbilek M
Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
[TBL] [Abstract][Full Text] [Related]
18. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.
Krebs MG; Blay JY; Le Tourneau C; Hong D; Veronese L; Antoniou M; Bennett I
ESMO Open; 2021 Apr; 6(2):100072. PubMed ID: 33676294
[TBL] [Abstract][Full Text] [Related]
19. Serial Cell-Free DNA Sequencing in
Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
